drugset / Trial / NCT07209163
Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
In decades, the outcome of patients with peripherial T-cell lymphomas is dismal, especially in relapsed or refractory population. After failure to the frontline treatment, patients have limited treatment options and elderly population usually have no chance to undergo transplantation due to age or comorbidity, etc. EZH2 inhibitor like Tazemetostat or SHR 2554 has been demonstrated its anti-tumor activity in PTCL either alone or in combination with other targeted agents. This study aims to explore the efficacy and safety of Tazemetostat in combination with Linperlisib/Golidocitinib in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma in the patients with peripheral T-cell lymphoma according to next-generation sequesing results.
Timeline
- Start
- 2025-10
- Primary completion
- 2026-03
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Golidocitinib | Small molecule | 150 mg | — |
| Subject | Linperlisib | Small molecule | 60 mg | — |
| Subject | Tazemetostat | Small molecule | 800 mg | Oral |